Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05925608
Other study ID # 05063
Secondary ID
Status Enrolling by invitation
Phase Phase 1
First received
Last updated
Start date August 23, 2023
Est. completion date December 2024

Study information

Verified date June 2023
Source BioCardia, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study will utilize allogenic bone marrow-derived culture-expanded MSC that are expanded from the NK1R+ Mesenchymal stem cells as a therapy for chronic ischemic left ventricular dysfunction delivered using the investigational Helix transendocardial delivery catheter.


Description:

Chronic heart failure is in need of new therapies. Over the past few years, cardiovascular regenerative medicine using bone marrow-derived cells has emerged as a new treatment strategy that could have tremendous benefit in treating heart failure. At present, several types of adult bone marrow derived stem cells hold great promise to treat heart failure. Allogenic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as having potential to provide a safe and effective treatment for patients with ischemic heart failure. Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue). The CardiALLO cell therapy is an allogenic bone marrow-derived NK1R+ selected and culture-expanded mesenchymal stem cells that will be delivered intramyocardially using the investigational Helix delivery catheter. The purpose of this study is to determine the safety, optimal dose and efficacy of CardiALLO cell therapy system in patients with post-myocardial infarction heart failure.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 9
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - New York Heart Association (NYHA) Class II or III - Diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction - Left ventricular ejection fraction between 20% and 40% - On stable, guideline-directed medical and device therapy, as appropriate Exclusion Criteria: - Other cardiovascular or medical history parameters, as appropriate, that may preclude safe administration of the study treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
BioCardia, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment-emergent serious adverse events Incidence of TE-SAE defined as a composite of death, non-fatal MI, stroke, worsening HF (requiring admission, iv diuretics and/or inotropics), myocardial perforation (with tamponade), ventricular arrythmias >15 seconds Through 30 days post-procedure.
Primary Composite endpoint consisting of all cause or cardiac death, non-fatal cardiac-related hospitalizations and functional capacity measured using the 6 minute walk distance. The primary efficacy endpoint is a composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis. The tiers, starting with the most serious events, would be (1) all cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement, ordered by time to event; (2) non-fatal MACCE events excluding those deemed procedure related occurring within the first 7 days (heart failure hospitalization, stroke or MI) ordered by time to event, and (3) change for 6MWD. Through Month 12
Secondary Overall survival Overall survival time Through 12 months
Secondary Major Adverse Cardiac Events (MACE) A composite of all-cause death, hospitalization for worsening heart failure, nonfatal recurrent myocardial infarction, placement of a left ventricular assist device [LVAD], or heart transplantation) Through 12 months
Secondary Minnesota Living with Heart Failure Questionnaire Self-reported questionnaire asking about heart failure symptoms with lower score being better Through 12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03227393 - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG N/A
Recruiting NCT04528004 - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Early Phase 1
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting NCT05988749 - Digital Remote Home Monitoring for Heart Failure N/A
Not yet recruiting NCT06240403 - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus Phase 2
Recruiting NCT04950218 - The Psoriasis Echo Study
Suspended NCT04701112 - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure N/A
Completed NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Enrolling by invitation NCT03903107 - The Fluoroless-CSP Trial Using Electroanatomic Mapping N/A
Withdrawn NCT04872959 - TRANSFORM Heart Failure With Reduced Ejection Fraction N/A
Completed NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT03553303 - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin Phase 4
Recruiting NCT04083690 - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT06121323 - Physiological Effects of Lactate in Individuals With Chronic Heart Failure N/A
Completed NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A